Alios BioPharma Inc., part of the Janssen Pharmaceutical Companies, is a clinical stage biopharmaceutical company in South San Francisco, California that is developing novel antiviral therapies for the treatment of respiratory diseases. Founded in 2008, Alios’ virology discovery and development platform consists of a proprietary chemical library of nucleoside analogs as well as novel virology-based screening systems. Alios is developing a portfolio of potential therapeutics for viral infections including respiratory syncytial virus (RSV), influenza, rhinovirus, and coronavirus.
Alios’ lead compound, AL-8176, is a first-in-class, oral, anti-RSV nucleoside analog that is currently in Phase 2a studies for the treatment of RSV. AL-8176 is designed to inhibit the replication of the RSV by acting on the viral polymerase. In vitro studies of the compound demonstrate potent and highly selective inhibition of both RSV laboratory-adapted A and B strains as well as a range of diverse clinical isolates. In addition, administration of AL-8176 resulted in potent multi-log suppression of RSV in an in vivo preclinical model. Phase 1 studies have been completed and there were no serious adverse events being reported and no adverse events leading to discontinuation.
Alios has a number of preclinical programs targeting Influenza, Rhinovirus and RSV, diseases that infect millions of patients worldwide on an annual basis and cause significant morbidity and mortality.